Media

Racura CEO and Managing Director Dr Daniel Tillett speaks with ausbiz about the company’s recent major milestone – the first patient has been safely and successfully dosed for the RC220 Phase 1 clinical trial in advanced solid tumours. Watch the full interview via this link.

Racura Oncology CEO and MD Daniel Tillett speaks with Proactive about the activation of the first Australian clinical site for the RC220 Phase I solid tumour trial. Dr Tillett confirms that the trial is now underway and open to patient enrolment. Watch the full interview below. Additional report can be found here.

Racura Oncology Executive Chair Dr Peter Smith speaks with Stockhead about the recent ethics approval for the company’s RC220 bisantrene Phase 1 clinical trial in solid tumour. The full report can be accessed via this link.

Racura Oncology Executive Chair Dr Peter Smith speak with Proactive about the approval the company has received from the Bellberry Human Research Ethics Committee (HREC). The approval allows the company to move forward with its Phase 1 clinical trial for RC220, a new formulation of bisantrene. The full report can be accessed via this link.

Racura CEO and Managing Director Dr Daniel Tillett speaks with ausbiz’s Juliette Saly about the ethics approval for the RC220 bisantrene Phase 1 clinical trial. Watch the full video via this link.

Racura CEO and Managing Director Dr Daniel Tillett speaks with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Dr Tillett discussed the challenges of chemotherapy, including severe side effects, and how Racura Oncology is working to minimise these risks while enhancing treatment effectiveness.

Proactive reports on the outlook of the oncology therapeutics market, naming Racura Oncology, alongside its peer companies, one of the most promising to look out for. Read the full article via this link.

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. In this episode, Fraser Palamara takes a look at Racura Oncology (ASX:RAC).

Racura Oncology is reformulating bisantrene (RAC-220) to prevent chemotherapy-induced heart damage, with a phase 1 cardioprotection trial planned for early 2025. The trial will enroll 25-40 patients across multiple sites. The company has also reported promising results from a phase 1b/2 trial using the original bisantrene formulation (RC-110) in treating acute myeloid leukemia.  Read the…